Pages that link to "Item:Q7807"

← Main section in publication (Q7807)

What links here

Page:  Namespace:  all (Main) Talk User User talk Wikibase.slis.ua.edu Wikibase.slis.ua.edu talk File File talk MediaWiki MediaWiki talk Template Template talk Help Help talk Category Category talk Item Item talk Property Property talk Module Module talk   Invert selection

Filters

Hide transclusions | Hide links | Hide redirects

The following pages link to Main section in publication (Q7807):

View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)

• Introduction section from DOI: 10.3390/pathogens9020148 (Q7903) ‎ (← links)
• Novel Coronavirus 2019-nCoV section from DOI: 10.3390/pathogens9020148 (Q7904) ‎ (← links)
• Transmission and Symptoms section from DOI: 10.3390/pathogens9020148 (Q7905) ‎ (← links)
• Perspectives on Biopharmaceuticals Development section from DOI: 10.3390/pathogens9020148 (Q7906) ‎ (← links)
• Concluding Remarks section from DOI: 10.3390/pathogens9020148 (Q7907) ‎ (← links)
• Introduction (Main section from DOI: 10.7326/m20-0504) (Q7922) ‎ (← links)
• Results (Main section from DOI: 10.7326/m20-0504) (Q7926) ‎ (← links)
• Discussion (Main section from DOI: 10.7326/m20-0504) (Q7927) ‎ (← links)
• Section 1: Introduction (from DOI: 10.1080/22221751.2020.1735265) (Q8394) ‎ (← links)
• Section 2: Protection requirements of medical personnel (from DOI: 10.1080/22221751.2020.1735265) (Q8395) ‎ (← links)
• Section 3: Diagnosis and treatment of SARS-CoV-2 infected patients (from DOI: 10.1080/22221751.2020.1735265) (Q8399) ‎ (← links)
• Section 3.5: Treatment (from DOI: 10.1080/22221751.2020.1735265) (Q8408) ‎ (← links)
• Section 4: Protection and transfer (from DOI: 10.1080/22221751.2020.1735265) (Q8417) ‎ (← links)
• Section 5: Criteria of isolation release and discharge (from DOI: 10.1080/22221751.2020.1735265) (Q8418) ‎ (← links)
• Section 1: Introduction (from DOI: 10.1038/s41392-020-0110-5) (Q8462) ‎ (← links)
• Section 2: The concept of CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8463) ‎ (← links)
• Section 3: Factors regulating CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8466) ‎ (← links)
• Section 4: Therapeutic targeting of CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8486) ‎ (← links)
• Section 5: Conclusions and perspectives (from DOI: 10.1038/s41392-020-0110-5) (Q8491) ‎ (← links)
• Section 1. Introduction (from DOI: 10.3390/v12020211) (Q10062) ‎ (← links)
• Section 2. Traditional Methods of Diagnosing Infections (from DOI: 10.3390/v12020211) (Q10063) ‎ (← links)
• Section 3. Studying Viral Pathogens with High Throughput Sequencing (HTS) (from DOI: 10.3390/v12020211) (Q10064) ‎ (← links)
• Section 4. Long Read Sequencing (from DOI: 10.3390/v12020211) (Q10073) ‎ (← links)
• Section 5. Obstacles to Overcome in the Nearest Future (from DOI: 10.3390/v12020211) (Q10074) ‎ (← links)
• Section 6. Conclusions (from DOI: 10.3390/v12020211) (Q10075) ‎ (← links)
• Section 1: Introduction (from DOI: 10.1016/j.jcv.2020.104372) (Q10717) ‎ (← links)
• Section 2: Is SARS-CoV-2 a congenital or perinatally-acquired pathogen for the neonate? (from DOI: 10.1016/j.jcv.2020.104372) (Q10718) ‎ (← links)
• Section 3: Conclusions and priorities for future research (from DOI: 10.1016/j.jcv.2020.104372) (Q10722) ‎ (← links)
• Section 1: Introduction (from DOI: 10.1007/s11886-020-01292-3) (Q10734) ‎ (← links)
• Section 2: Biology of SARS-CoV-2 (from DOI: 10.1007/s11886-020-01292-3) (Q10735) ‎ (← links)
• Section 3: The Role of Host Immune Response (from DOI: 10.1007/s11886-020-01292-3) (Q10736) ‎ (← links)
• Section 4: Viral Toxicity and Myocardial Injury in COVID-2 (from DOI: 10.1007/s11886-020-01292-3) (Q10737) ‎ (← links)
• Section 5: Immune Responses to SARS-CoV-2 Infection and the Heart (from DOI: 10.1007/s11886-020-01292-3) (Q10738) ‎ (← links)
• Section 6: Host-Specific Variations in COVID-19 Immune Response (from DOI: 10.1007/s11886-020-01292-3) (Q10739) ‎ (← links)
• Section 7: Treatments for SARS-CoV-2 Infection (from DOI: 10.1007/s11886-020-01292-3) (Q10740) ‎ (← links)
• Section 8: Conclusion (from DOI: 10.1007/s11886-020-01292-3) (Q10741) ‎ (← links)
• Section 1: Introduction (from DOI: 10.1186/s13054-020-02882-x) (Q10751) ‎ (← links)
• Section 2: COVID-19: Potential factors contributing to ICU delirium (from DOI: 10.1186/s13054-020-02882-x) (Q10752) ‎ (← links)
• Section 3: COVID-19: Neuro-invasive potential of SARS-nCoV-2 as cause of delirium (from DOI: 10.1186/s13054-020-02882-x) (Q10753) ‎ (← links)
• Section 4: COVID-19: ICU delirium management:potential problems and solutions (from DOI: 10.1186/s13054-020-02882-x) (Q10754) ‎ (← links)
• Section 5: Conclusions (from DOI: 10.1186/s13054-020-02882-x) (Q10755) ‎ (← links)
• Section 1: Introduction (from DOI:10.14218/ERHM.2020.00023) (Q10798) ‎ (← links)
• Section 2: Methods (from DOI:10.14218/ERHM.2020.00023) (Q10799) ‎ (← links)
• Section 3: Results (from DOI:10.14218/ERHM.2020.00023) (Q10800) ‎ (← links)
• Section 4: Discussion (from DOI:10.14218/ERHM.2020.00023) (Q10801) ‎ (← links)
• Section 5: Future directions (from DOI:10.14218/ERHM.2020.00023) (Q10802) ‎ (← links)
• Section 6: Conclusions (from DOI:10.14218/ERHM.2020.00023) (Q10803) ‎ (← links)
• Section 1: Introduction (from DOI: 10.1007/s11886-020-01293-2) (Q10986) ‎ (← links)
• Section 2: SARS-CoV-2 Biology and Clinical Implications (from DOI: 10.1007/s11886-020-01293-2) (Q10987) ‎ (← links)
• Section 3: Cardiovascular Comorbidities and COVID-19 Outcomes (from DOI: 10.1007/s11886-020-01293-2) (Q10988) ‎ (← links)

View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)